Spironolacton-Tchaikapharma stimulates the excretion of urine in patients who have fluid accumulation in the tissues (edema) or in the abdominal cavity (ascites) by increasing the amount of sodium (salt) excreted in the urine.
Spironolacton-Tchaikapharma is indicated for the treatment of:
– congestive cardiac failure;
– hepatic cirrhosis with ascites and oedema;
– malignant ascites;
– nephrotic syndrome;
– diagnosis and treatment of primary aldosteronism (syndrom of Conn);
– hypertension in combination with other antihypertensive products, especially when prone to hypokalaemia.
Subject to medical prescription.
Concentration and pharmaceutical form: 25 mg, 50 mg, 100 mg film-coated tablets